当前位置: X-MOL 学术Leukemia › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.
Leukemia ( IF 12.8 ) Pub Date : 2020-02-25 , DOI: 10.1038/s41375-020-0778-0
Prithviraj Bose 1 , Srdan Verstovsek 1 , Jorge E Cortes 1 , Susan Tse 1 , Yvonne Gasior 1 , Nitin Jain 1 , Elias J Jabbour 1 , Zeev Estrov 1 , Yesid Alvarado 1 , Courtney D DiNardo 1 , Naveen Pemmaraju 1 , Steven M Kornblau 1 , Tapan M Kadia 1 , Naval G Daver 1 , Kiran Naqvi 1 , Nicholas J Short 1 , Lucia Masarova 1 , John Villareal 1 , Sherry A Pierce 1 , Graciela Nogueras-Gonzalez 2 , Xuelin Huang 2 , Guillermo Garcia-Manero 1 , Hagop M Kantarjian 1 , Farhad Ravandi 1
Affiliation  



中文翻译:

鲁索替尼和地西他滨治疗骨髓增生后肿瘤急性髓系白血病患者的 1/2 期研究。

更新日期:2020-02-26
down
wechat
bug